title: [New advances in the treatment of inflammatory bowel disease].
abstract: Several studies on conventional drugs and new treatments in inflammatory bowel disease were presented in Digestive Disease Week 2013. Various studies have compared infliximab and cyclosporin in corticosteroid-refractory ulcerative colitis in clinical practice, providing complementary information to the CYSIF clinical trial. For the first time, a clinical trial has evaluated the efficacy of adalimumab in preventing recurrence of Crohn's disease after surgery. The results of some studies suggest that thiopurines improve response to infliximab, in both Crohn disease and ulcerative colitis. Finally, several studies were presented on new drugs with new therapeutic targets, such as vedolizumab, in the treatment of inflammatory bowel disease. The preliminary results of the ASTIC trial were reported, which evaluated the safety and efficacy of bone marrow transplantation in Crohn's disease.
authors.affiliation: Servicio de Aparato Digestivo, Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria Princesa (IP) y Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, España. Electronic address: mariachs2005@gmail.com.
authors.forename: María
authors.initials: M
authors.lastname: Chaparro
mesh_terms: D003093:Colitis, Ulcerative / Q000188:drug therapy; D003424:Crohn Disease / Q000188:drug therapy; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000628:therapy*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D014409:Tumor Necrosis Factor-alpha
keywords: Adalimumab; Colitis ulcerosa; Crohn disease; Enfermedad de Crohn; Enfermedad inflamatoria intestinal; Golimumab; Inflammatory bowel disease; Infliximab; Natalizumab; Thiopurines; Tiopurinas; Ulcerative colitis; Vedolizumab